MIVT right back up to .60...this one is getting more and more expsure for their stent coatings..have seen it posted by investors, not sites as much, in several places. As story grows so should the price...they have something no one else has and they have patents to protect their technology.
(COMTEX) B: First Phase of MIV Therapeutics Canadian R&D Program is Succes
B: First Phase of MIV Therapeutics Canadian R&D Program is Success ( financialwi
Feb 11, 2004 (financialwire.net via COMTEX) -- (FinancialWire) MIV Therapeutics
(OTCBB: MIVT; BSE: MIV; Frankfurt: MIV1) said it has successfully completed the
first phase of its Hydroxyapatite (HA) Drug-Eluting Stent Coating R&D Program
sponsored in part by the Canadian Government.
The University of British Columbia has submitted its final report to the Natural
Sciences and Engineering Research Council of Canada (NSERC) which provided a
grant in support of the research program entitled "Functionally Gradient Calcium
Phosphate Coatings for Stents."
The research activities were conducted by the University of British Columbia,
UBCeram -- Metals and Materials Engineering, in close cooperation with MIVT's
R&D team, under a Collaborative Research and Development Agreement.
The objective of the program was to develop multilayer biocompatible and
bioactive calcium phosphate functionally graded coatings on stents.
Two types of coatings were developed.
An extensive range of tests were performed to validate the reproducibility and
integrity of the above coatings, and their suitability for use on cardiovascular
stents and other medical devices, with a focus on drug encapsulation and drug
eluting applications.
"We have completed all the tasks related to the deposition and evaluation of
submicron film uniformity on the complex stent surface. We have evaluated
alternative methods for such film deposition as well as chemical surface
modification methods for improved surface coverage and adhesion of the coatings.
This NSERC-sponsored program resulted in the successful development of two
alternative coating technologies that produced coatings with excellent
properties, ideally suited for drug encapsulation for drug-eluting
purposes," said Dr. Tom Troczynski, Professor of Ceramics at The University
of British Columbia Metals and Materials Engineering Department, and MIVT's Vice
President of Coatings.
MIV Therapeutics is covered by Investrend Research affiliate SISM Research's
analyst, Ernest C. Schlotter. On September 22, 2003, Schlotter initiated
coverage with a "Buy" rating and a $1.50 target, which was reiterated
October 19. SISM Research is distributed by the Investrend Research Syndicate.
Both SISM Research and Investrend Research are members FIRST Research Consortium
at firstresearchconsortium.com, and participates in the
organization's standards development panel for independent research providers.
The "Standards for Independent Research Providers" may be viewed at
investrend.com .
According to the New York Times (NYSE: NYT), a survey by Charles Schwab & Co.
(NYSE: SCH) reveals an astonishing 78 percent of active stockholders now
"value research from independent firms over analysis by Wall Street firms
with financial ties to the companies they are rating." A survey at
Investopedia reveals that 74.7% of investors say that "legitimate fee-based
research is objective and useful," and 70.9% say that a company that enrolls for
"legitimate fee-based research is making a positive statement about its
investment potential."
The fee for SISM coverage was $16,500, and the fees were paid by the company to
SISM. There are never any fees associated with FinancialWire, which
independently covers a wide range of corporate news, including but not limited
to those that are or have been enrolled in Investrend's platforms.
Complete information about any company enrolled in an Investrend Research
affiliate platform, including disclosures and disclaimers, is available at the
company's InvestorPower page at
investrend.com , and on each report
and press release, and investors are advised to read those disclosures carefully
before trading in the equities of any enrolled company.
For up-to-the-minute news, features and links click on
financialwire.net
FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
investrend.com
The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: investrend.com
URL: financialwire.net
(C) 2004 financialwire.net, Inc. All rights reserved.
-0-
*** end of story *** |
